AE	Adverse event
ALK	Anaplastic lymphoma kinase
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
BMs	Brain metastases
CI	Confidence interval
CNS	Central nervous system
CPK	Creatine phosphokinase
DLT	Dose-limiting toxicity
DOR	Duration of response
EGFR	Epidermal growth factor receptor
EMA	European Medicines Agency
FDA	Food and Drug Administration
IC	Intracranial
IC-ORR	Intracranial overall response rate
ICI	Immune checkpoint inhibitor
IHC	Immunohistochemistry
ISH	In situ hybridization
MAPK	Mitogen-activated protein kinase
MET	Mesenchymal–epithelial transition factor
mPFS	Median progression-free survival
NGS	Next-generation sequencing
NR	Not reached
NSCLC	Non-small cell lung cancer
ORR	Overall response rate
OS	Overall survival
PCR	Polymerase chain reaction
PD-L1	Programmed death-ligand 1
PFS	Progression-free survival
QT	QT interval on electrocardiogram
RT-PCR	Reverse transcription polymerase chain reaction
TKI	Tyrosine kinase inhibitor
TRK	Tropomyosin receptor kinase